In this large, multicenter analysis, DAA treatment with SOF was not associated with the development of de novo HCC, after adjusting for sex, age, serum albumin, ALT, platelet count, AFP, eGFR, cirrhosis, and treatment experience. This evidence concerns the gene GPT and hepatocellular carcinoma.